TFF3 and Barrett esophagus: The BEST3 trial is a multi-site cluster-randomised controlled trial to evaluate the ability of the CytospongeTM-TFF3 test to identify BE among patients with gastro-oesophageal reflux predominant symptoms not meeting guidelines for referral.